FDA 483 - Hugel Inc. - March 10, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Hugel, Inc. (Site 2) in Chuncheon-si, Republic of Korea, was inspected for its drug substance and drug product manufacturing facilities. The inspection revealed significant deficiencies across multiple areas, including inadequate cleaning and disinfection programs, compromised laboratory data integrity, and critical failures in aseptic processing and environmental monitoring. The firm's quality unit oversight was also found to be insufficient, indicating a broad lack of control over GMP operations.
ID · 244a9899-9c37-4cf3-94cd-197b4717200f